To compare baseline characteristics , treatment frequency , visual acuity ( VA ) , and morphologic outcomes of eyes with > 50 % of the lesion composed of blood ( B50 group ) versus all other eyes ( Other group ) enrolled in the Comparison of Age-Related Macular Degeneration Treatments Trials ( CATT ) .